Consensus on the secondary prevention of primary liver cancer Yuemin NanXiaoyuan XuChinese Society of Hepatology, Chinese Medical Association Consensus Open access 30 November 2021 Pages: 1289 - 1300
Are herbals more hepatotoxic than prescription medications? Vincent L. ChenRobert J. Fontana Editorial 05 October 2021 Pages: 1301 - 1304
Gut microbiota alteration in hepatobiliary diseases: cause-and-effect relationship Xiaoyan GuoYanmei JiaoFu-Sheng Wang Editorial 15 November 2021 Pages: 1305 - 1308
Application of CRISPR-Cas9 based gene editing to study the pathogenesis of colon and liver cancer using organoids Gayatri RamakrishnaPreedia E. BabuNirupma Trehanpati Review Article 01 October 2021 Pages: 1309 - 1317
Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis Xiaoning WuJia HongJidong Jia Original Article 29 November 2021 Pages: 1318 - 1327
Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients Hye Yeon ChonSang Hoon AhnSeung Up Kim Original Article 20 November 2021 Pages: 1328 - 1336
Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case–control study Hui-Hui LiuYe-Xuan CaoJian-Jun Li Original Article 09 October 2021 Pages: 1337 - 1346
Hepatic fibrosis is associated with an increased rate of decline in bone mineral density in men with nonalcoholic fatty liver disease Ji Won YoonMin Joo KimMin-Sun Kwak Original Article 04 October 2021 Pages: 1347 - 1355
A systematic review and meta-analysis of anticoagulation therapy for portal vein thrombosis in patients with cirrhosis: to treat or not to treat? Shujie DongHuihong QiRongsheng Zhao Original Article 06 September 2021 Pages: 1356 - 1375
‘First week’ is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure Ashok ChoudhuryRajan VijayaraghavanAPASL ACLF Research Consortium (AARC) for APASL ACLF Working Party Original Article 04 October 2021 Pages: 1376 - 1388
Establishment of a murine model of acute-on-chronic liver failure with multi-organ dysfunction Nidhi NautiyalDeepanshu MaheshwariShiv Kumar Sarin Original Article 25 August 2021 Pages: 1389 - 1401
Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial Fanping MengJinfang ZhaoFu-Sheng Wang Original Article Open access 30 November 2021 Pages: 1402 - 1412
Sex and regional disparities in incidence of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis Lun-Jie YanSheng-Yu YaoTao Li Original Article 03 September 2021 Pages: 1413 - 1420
Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines Wei TengTing-Tsung ChangJaw-Ching Wu Original Article 06 November 2021 Pages: 1421 - 1430
Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial Ming ShiYuan-Yuan LiFu-Sheng Wang Original Article Open access 29 November 2021 Pages: 1431 - 1441
Determination of Turkish norms of psychometric tests for diagnosing minimal hepatic encephalopathy and proposal of a high sensitive screening test battery Burak ÖzbaşOnur KeskinCihan Yurdaydin Original Article 03 June 2021 Pages: 1442 - 1455
Herbal and dietary supplement-induced liver injury in Taiwan: comparison with conventional drug-induced liver injury Yi-Shin HuangTing-Tsung ChangYi-Hsiang Huang Original Article 11 August 2021 Pages: 1456 - 1465
Correction to: Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients Huei-Ru ChengHung-Chih YangJia-Horng Kao Correction 25 September 2021 Pages: 1466 - 1467